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Introduction
Systemic sclerosis (SSc) is a rare, chronic, autoim-
mune disease which is characterized by a widespread
vasculopathy and a profound fibrosis of the skin and
internal organs. The vascular involvement manifests
itself in decreased number of capillary vessels,
enlargement of the remaining capillaries and/or prolif-
erative angiopathy of small arteries [1]. The excessive
fibrosis which is considered a hallmark of SSc results
from overproduction of extracellular matrix compo-
nents by activated fibroblasts [2].
Despite the progress in our understanding of the
pathogenesis of SSc, the factors responsible for the
development of the disease are still unclear [2]. More-
over, there is still lack of effective treatment strategies
for SSc. [3]. The TNF-like weak inducer of apoptosis
(TWEAK) is a recently recognized multifunctional
cytokine which regulates wound healing and tissue
remodeling [4].
TWAEK, acting through the polypeptide growth-
factor-inducible Fn14 receptor activates several intra-
cellular signaling pathways, including NFkappaB,
leading to a wide range of cellular responses crucial to
tissue remodeling, including angiogenic, proliferative,
and inflammatory responses (reviewed in details in
references 4 and 5).
TWEAK contributes to angiogenesis through stim-
ulation of migration, proliferation and survival of
endothelial cells [4,5]. Moreover, TWEAK stimulates
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smooth muscles cells proliferation [4,5] which might
be of importance for new vessel formation, but also
may contribute to pathogenesis of proliferative
angiopathy seen in SSc-related pulmonary arterial
hypertension or scleroderma renal crisis.
TWEAK can also activate human fibroblasts. In
human dermal fibroblasts and corneal myofibroblasts
TWEAK induced production of proinflammatory
cytokines and chemokines: interleukin 6 (IL-6), inter-
leukin 8 (IL-8), RANTES (regulated on activation,
normal T expressed and secreted), interferon-γ-
inducible protein-10 (IP-10) and/or MCP-1 [6,7].
Human gingival fibroblasts responded to TWEAK
stimulation with increased expression of adhesion
molecules (VCAM-1 and ICAM-1), IL 8 and vascular
endothelial growth factor (VEGF) [8]. Interestingly,
TWEAK-mediated induction of ICAM-1, IL-8, MCP-
1, RANTES and VEGF were augmented synergistical-
ly by transforming growth factor-B (TGF-β) [7,8], a
cytokine which is considered of key importance for the
pathogenesis of SSc-related fibrosis [9]. 
Angiogenesis and activation of fibroblasts are key
events in both wound healing and pathogenesis of SSc.
Deregulated production of TWEAK might therefore
contribute to development of SSc. Indeed, Yanaba et
al. have recently reported increased TEAWK levels in
the sera from SSc patients [10]. The cellular source of
these increased TWEAK levels in SSc have not been
indicated so far.
Since monocytes/macrophages have been shown to
express TWEAK [11] we hypothesized that increased
production of TWEAK by the peripheral blood
mononuclear cells (PBMC) might be a source of
increased levels of TWEAK in the blood of SSc
patients. To address this hypothesis, the production of
TWEAK was investigated in the PBMC from patients
with SSc and healthy controls. Moreover, TWEAK
production was correlated with clinical features of SSc.
Materials and methods
Patients. 24 patients with SSc (20 female and 4 men) were investi-
gated. Patients selected for the study fulfilled the ACR classification
criteria for SSc. [12] or they had Raynaud's phenomenon and at least
one of the following: microangiopathy typical for SSc in capil-
laroscopy, and/or autoantibodies typical for SSc, ,which is consistent
with the definition of early SSc as proposed by LeRoy et al. [13].
To avoid modification of the activity of leucocytes by immuno-
suppressive drugs only patients who had not taken any immuno-
suppressive therapies or in whom immunosuppressive therapies
had been stopped at least 6 months before blood collection were
considered eligible. SSc patients were classified as having diffuse
cutaneous SSc (dSSc) or limited cutaneous SSc (lSSc) based on
criteria by LeRoy et al. [14].
Duration of Raynaud's phenomenon as well as duration of the
disease, calculated from the time of the first non-Raynaud's symp-
tom attributable to SSc, were recorded for every patient. In agree-
ment with generally accepted criteria, early disease was defined as
shorter than 3 years in diffuses SSc patients or shorter than 5 years
duration in patients with limited SSc measured from first non-Ray-
naud-symptom. 
The presence of scleroderma interstitial lung disease was
defined based on the presence of features of interstitial fibrosis
and/or "ground glass" opacifications in high resolution computed
tomography (HRCT) of the lungs. Lung volumes were evaluated
by spirometry. Pulmonary hypertension was defined as pulmonary
artery systolic pressure higher than 45 mmHg, as measured by
echo-Doppler. Patients without tricuspid regurgitation were con-
sidered as having normal pulmonary artery pressure. The presence
of antinuclear antibodies and anticentromere (ACA) antibodies
was evaluated by indirect immunofluorescence on Hep-2 cells and
the presence of anti-topoizomerase I (anti-topo, anti-Scl70) anti-
bodies – by ELISA technique. ESR and CRP concentrations were
used as laboratory parameters of activity of inflammation. Capil-
laroscopic assessment consisted of evaluation of the four fingers
(II-V) of both hands with regard to the presence of megacapillar-
ies, bushy capillaries and/or avascular areas (defined as lack of at
least three consecutive capillaries). Patient was considered as hav-
ing scleroderma-related microangiopthy when at least two mega-
capillaries per finger in at least two fingers could be found. In addi-
tion, capillaroscopic patterns were classified according to the clas-
sification by Marique et al. as "slow" pattern characterized by reg-
ular distribution of the capillaries, preserved architecture of vascu-
lar layout and the presence of megacapilaries, or as 'active" pattern
characterized by irregular drop-out of capillaries resulting in dis-
rupted architecture of vascular layout, the presence of megacapil-
laries and/or bushy capillaries [15].
Control group consisted of 14 healthy subjects (12 female and
2 men). Clinical characteristics of the patients and controls is given
in Table 1.
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Table 1. Clinical characteristics of the patients with systemic scle-
rosis and the control group
*P<0.05; ACA=anticentromere antibodies, ACR=American College of
Rheumatology, ANA=antinuclear antibodies, dSSc=diffuse cutaneous sys-
temic sclerosis, HRCT=high resolution computed tomography, lSSc=lim-
ited cutaneous systemic sclerosis, SLD=scleroderma lung disease
PBMC cultures and measurements of TWEAK in super-
natants. Heparin anticoagulated peripheral blood samples were
obtained from cubical vein between 7 and 8 a.m. after patient hav-
ing fasted for at least 10 hours.
Peripheral blood mononuclear cells (PBMC) were isolated
from the whole blood using density gradient centrifugation on
Histopaque. The isolated PBMC were resuspended in RPMI medi-
um supplemented with 5% fetal calf serum at a density 105 cells/ml
and cultured at 37°C under 5% CO2 for 24 hours. Subsequently the
cells were centrifuged and supernatants were collected and frozen
at -80°C until measurements.
Evaluation of TWEAK concentration in the supernatants was
performed using commercially available ELSA kits (Bender
MedSystems). 
Statistical analysis. For the assessment of between-group compar-
isons the Mann-Whitney U test, and for assessment of correlation the
Spearman correlation test were used. The differences were consid-
ered significant at p value lower than 0.05. All results are expressed
as mean±standard deviation (SD) unless stated otherwise.
Results
Comparison of TWEAK production between
SSc patients and healthy controls.
The majority (16 out of 24, 66.7%) of patients included
in our study had early SSc. There were no differences in
the total number of leukocytes or differential cell counts
numbers between SSc patients and the controls (data not
shown). TWEAK was detected in the supernatants from
PBMC cultures of all SSc patients and healthy controls.
There were no significant differences in the production
of TWEAK by the PBMC from patients with SSc and
those from healthy subjects – Fig. 1.
Although healthy controls were slightly younger
than patients with SSc we consider it unlikely that age
differences could significantly influence our results
since there were no correlations between age and
TWEAK production in the whole group (r=-0.004,
p=0.98), SSc patients (r=0.049, p=0.82) nor healthy
controls (r=0.9, p=0.91).
Associations of the production of TWEAK with
clinical features of systemic sclerosis.
To reveal potential role of TWEAK in the pathogene-
sis of scleroderma-related organ involvement we
searched for correlations/associations between
TWEAK production and clinical features of SSc.
TWEAK levels showed significant, inverse corre-
lation with the duration of Raynaud's phenomenon (r=-
0.54, p=0.007) (Table 2).
Moreover, PBMC from patients with "active" pat-
tern of capillary changes produced significantly lower
amounts of TWEAK (21.2±4.8 pg/105 cells) when com-
pared with PBMC from patients with "slow" pattern
(31.9±11.3 pg/105 cells, p=0.01) and healthy subjects
(27.5±7.1 pg/105 cells, p<0.05 vs patients with "active"
pattern). Since "active" pattern is associated with greater
damage of the capillaries, as indicated by the presences
of avascular areas, our findings might indicate that
lower production of TWEAK is associated with greater
capillary burden and subsequent tissue ischemia.
PBMC from patients with SLD tended to produce
lower amounts of TWEAK (24.2±8.7 pg/105 cells) as
compared with patients without SLD (30.6±9.0 pg/105
cells), however the differences were not significant
(p=0.088). There was also no significant correlation
between TWEAK production and FVC values. How-
ever, the majority of patients included in our study had
lung volumes within normal limits, this is greater than
80% of predicted, which could diminish the power of
this comparisons. 
We were not able to demonstrate any association
between production of TWEAK by PBMC and any
other clinical or laboratory indices in the studied
patients (Table 2).
Since only one patient had elevated pulmonary artery
systolic pressure and none of them had scleroderma renal
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Fig. 1. Concentration of TWEAK in cultures of peripheral blood
mononuclear cells from the whole group of patients with systemic
sclerosis, scleroderma patients with "active" and "slow" patterns in
capillaroscopy, and in healthy controls. *p<0.05 vs "slow" pattern
and healthy controls.
Table 2 Correlations between production of TWEAK by PBMC
and clinical and laboratory parameters of patients with systemic
sclerosis.
CRP=C-reactive protein, ESR=erythrocyte sedimentation rate,
,FVC=forced vital capacity, mRSS=modified Rodnan skin score,
PASP=pulmonary artery systolic pressure
crisis, we were unable to investigate associations of pro-
duction of TWEAK and these serious vascular compli-
cations of the disease. Also, a low number of patients
having active digital ulcers at the time of the study pre-
cluded statistical analysis of this complication.
Discussion
Our major finding is that diminished production of
TWEAK by PBMC is associated with greater microvas-
cular damage in SSc. In our study, PBMC from patients
with "active" capillaroscopic pattern, which is charac-
terized by greater capillary drop-outs, presence of avas-
cular areas and disorganization of capillary layout, pro-
duced significantly lower amounts of TWEAK as com-
pared with PBMC from SSc patients with "slow" capil-
laroscopic pattern which is characterized mainly by the
presence of megacapillaries. TWEAK production in
SSc patients with "active" capillary pattern was also sig-
nificantly lower than in healthy subjects. We also found
inverse correlation between TWEAK production and
duration of Raynaud's phenomenon in our SSc patients.
Raynaud's phenomenon is a universal and usually the
very first manifestation of SSc which may precede
development of other clinical manifestations by up to
several years. Raynaud's phenomenon preceding devel-
opment of definite SSc is usually accompanied by the
presence of microangiopathy indicating that microvas-
cular damage takes place from the earliest identifiable
stages of the disease. Indeed, Cutolo et al. found signif-
icant correlations between duration of Raynaud's phe-
nomenon and capillary damage, in particular capillary
loss and disorganization of vascular architecture, which
are typical features of "active" scleroderma pattern, in
patients with SSc [16]. In a recent prospective study
involving almost 600 patients with Raynaud's phenom-
enon followed-up for 20 years, capillary loss was a late
phenomenon associated with development of definite
SSc [17]. Taken together, our findings concerning
diminished production of TWEAK in patients with
greater microvascular damage and longer Raynaud's
phenomenon indicate that decreased production of
TWEAK is associated with more advanced vascular dis-
ease in SSc. Since TWEAK posses pro-angiogenic
activity it is tempting to speculate that decreased
TWEAK production may contribute to SSc-associated
vascular damage in SSc. This hypothesis is particularly
appealing in view of the fact that mononuclear cells are
the major constituents of the perivascular infiltrations
found in early SSc.
As discussed in the introduction, TWEAK, as a mul-
tifunctional cytokine, possesses a broad range of bio-
logical activities some of which might be potentially
detrimental in the SSc pathogenesis while the others,
such as pro-angiogenic activity of TWEAK, might be
potentially beneficial. Experimental studies using dif-
ferent models of autoimmune diseases such as rheuma-
toid arthritis (collagen-induced arthritis), systemic lupus
erythematosus (graft versus host disease), or multiple
sclerosis (experimental autoimmune
encephalomyelitis), indicate that TWEAK contributes
to the development of end-organ damage possibly
through involvement of maintenance of chronic inflam-
mation (reviewed in ref. 5). None of these disease mod-
els is however associated with profound fibrosis which
is the major feature and cause of mortality in SSc. In
vitro TWEAK activates fibroblasts to release proinflam-
matory mediators, some of which, such as IL-8 or MCP-
1 have been already implicated in the pathogenesis of
SSc [18]. However, TWEAK also inhibits differentia-
tion of human keratinocytes into myofibroblasts, cells
which possess pro-fibrotic phenotype [7].
So far, only one study concerning TWEAK in
patients with SSc. has been published recently. Yanaba
et al. reported that soluble TWEAK levels are elevat-
ed in the sera from patients with SSc compared with
healthy individuals and patients with lupus erythe-
matosus [10]. Interestingly, they found inverse associ-
ation between TWEAK levels and the presence of pul-
monary fibrosis which led them to a conclusion that
TWEAK has rather protective than deleterious role in
SSc. Generally, this is in agreement with our interpre-
tation of the current study suggesting that TWEAK
might be protective against vascular damage in SSc.
Elevated serum concentration of TWEAK may
result from excessive production or from deficient
clearance or receptor binding. The results of our study
indicate that, as expected, PBMC might be a potential
source of soluble TWEAK in the blood of both SSc
patients and healthy subjects. Although we did not find
significant differences in in vitro production of
TWEAK between PBMC from the whole group of SSc
patients and healthy controls, it might be argued that
there are numbers of active biological mediators in the
circulation of SSc patients which can activate PBMC
to release higher amounts of TWEAK in vivo. It could
also be speculated that other cell types might con-
tribute to increased TWEAK levels found in the sera of
SSc patients. Inflammatory leukocytes are considered
as major source of TWEAK, however it cannot be def-
initely ruled-out that other than PBMC cell types, such
as granulocytes, activated endothelial cells or platelets
might release TWEAK in vivo. 
On the other hand, it has recently been shown that cys-
teine reach scavenger receptor CD163 binds TWEAK
and CD163 positive macrophages can internalize
TWEAK decreasing levels of TWEAK [19,20]. Whether
CD163-depndent clearance of TWEAK could be respon-
sible for diminished amounts of TWEAK in PBMC cell
cultures needs to be determined. Elevated expression of
CD163 has been reported in chronic diseases such as ath-
erosclerosis, asthma, and celiac disease [20-22].
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Although we did not find significant associations
between TWEAK production by PBMC and other than
vascular, clinical or laboratory parameters of the dis-
ease, PBMC from patients with SLD tended to pro-
duce lower amounts of TWEAK compared with those
without any evidence of SLD. In general, this is in
agreement with observation of Yanaba et at who found
inverse correlations between serum TWEAK levels
and development of lung fibrosis [10].
It cannot be ruled out that our study is just under-
powered to reveal significant associations between
TWEAK production and lung fibrosis or other sclero-
derma related organ involvement. This seems possible
since the majority of patients included in our study had
early SSc and, possibly for this reason, infrequently
displayed severe organ involvement. Further, longitu-
dinal analysis is required to establish whether produc-
tion of TWEAK by PBMC is associated with develop-
ment of any scleroderma-associated organ complica-
tion. This hypothesis seems attractive in view of orig-
inal observations by Maricqe et al. revealing that
"active" capillaroscopic pattern was associated with
greater frequency and severity of organ involvement in
SSc which indicates that capillary damage plays a key
role in the pathogenesis of SSc [23]. Also, in a recent
study by Koenig et al. the occurrence of capillary loss
was associated with development of definite SSc. in
patients presenting with Raynaud's phenomenon [17].
In conclusion, the results of our study indicate that
PBMC may be a potential source of soluble TWEAK
in the blood. Factors responsible for increased produc-
tion of TWEAK in the blood of SSc patients need to be
determined.
Association between production of TWEAK by
PBMC and vascular features of SSc suggest that
TWEAK might have protective role against scleroder-
ma-associated vascular injury. Whether TWEAK
might appear useful in treating scleroderma associated
vascular disease requires further studies.
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